Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRDL | US
0.06
3.19%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
30/08/2024
1.94
1.92
1.94
1.87
Cardiol Therapeutics Inc. a clinical-stage life sciences company focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx which is in Phase II/III multi-national randomized double-blind and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19 as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville Canada.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
51.2%1 month
55.1%3 months
84.6%6 months
88.6%-
-
11.25
0.01
0.01
0.30
178.81
-
-31.66M
135.57M
135.57M
-
-
-
-
-108.44
2.93
1.13
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.26
Range1M
0.41
Range3M
1.42
Rel. volume
0.81
Price X volume
361.25K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LFCR | LFCR | Drug Manufacturers-Specialty & Generic | 4.38 | 135.21M | 14.81% | 19.08 | 241.85% |
Zomedica Pharmaceuticals Corp | ZOM | Drug Manufacturers-Specialty & Generic | 0.1289 | 128.64M | 1.90% | n/a | 1.10% |
Aceto Corporation | ACET | Drug Manufacturers-Specialty & Generic | 1.46 | 120.31M | -1.35% | n/a | 8.14% |
Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 0.8184 | 119.80M | 0.42% | n/a | 36.36% |
Assertio Therapeutics Inc | ASRT | Drug Manufacturers-Specialty & Generic | 1.18 | 112.50M | 1.72% | n/a | 30.76% |
INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 2.27 | 103.45M | 1.79% | n/a | 41.98% |
Karyopharm Therapeutics Inc | KPTI | Drug Manufacturers-Specialty & Generic | 0.7602 | 94.78M | -1.38% | n/a | -148.05% |
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 9.245 | 93.25M | 2.15% | n/a | 3.08% |
Relmada Therapeutics Inc | RLMD | Drug Manufacturers-Specialty & Generic | 2.8 | 84.49M | 6.06% | n/a | 0.00% |
Universe Pharmaceuticals INC | UPC | Drug Manufacturers-Specialty & Generic | 3.25 | 76.85M | -0.61% | n/a | 13.87% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Unifi Inc | UFI | Textile Manufacturing | 6.83 | 124.66M | -2.84% | n/a | 52.56% |
Culp Inc | CULP | Textile Manufacturing | 5.02 | 62.60M | 0.20% | n/a | 11.29% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.76 | 11.69M | 7.80% | n/a | 422.08% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.97% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.30 | - | Cheaper |
Ent. to Revenue | 178.81 | - | Cheaper |
PE Ratio | - | 28.13 | - |
Price to Book | 11.25 | 11.07 | Par |
Dividend Yield | - | - | - |
Std. Deviation (3M) | 84.56 | - | Par |
Debt to Equity | 0.01 | -0.91 | Expensive |
Debt to Assets | 0.01 | 0.45 | Cheaper |
Market Cap | 135.57M | - | Emerging |